253 related articles for article (PubMed ID: 16620456)
1. Schizophrenia.
Lawrie S; McIntosh A; Nadeem Z
Clin Evid; 2005 Dec; (14):1306-30. PubMed ID: 16620456
[No Abstract] [Full Text] [Related]
2. Schizophrenia.
Nadeem Z; McIntosh A; Lawrie S
Clin Evid; 2003 Dec; (10):1208-37. PubMed ID: 15555143
[No Abstract] [Full Text] [Related]
3. Schizophrenia.
McIntosh A; Lawrie S
Clin Evid; 2004 Dec; (12):1502-33. PubMed ID: 15865730
[No Abstract] [Full Text] [Related]
4. [Atypical antipsychotics].
Naber D
Nervenarzt; 2000 May; 71(5):327-8. PubMed ID: 10846707
[No Abstract] [Full Text] [Related]
5. [Zotepin--its value and potentials for further development].
Nervenarzt; 1994 Jul; 65(7 Suppl):1-8. PubMed ID: 9218060
[No Abstract] [Full Text] [Related]
6. Prevention of relapse in schizophrenia.
Geddes J
N Engl J Med; 2002 Jan; 346(1):56-8. PubMed ID: 11778005
[No Abstract] [Full Text] [Related]
7. [Late schizophrenia].
Morishita S
Ryoikibetsu Shokogun Shirizu; 2003; (38):80-3. PubMed ID: 12876935
[No Abstract] [Full Text] [Related]
8. Prevention of relapse in schizophrenia.
Lieberman J; Stroup S; Schneider L
N Engl J Med; 2002 May; 346(18):1412-3; author reply 1412-3. PubMed ID: 11987324
[No Abstract] [Full Text] [Related]
9. Treatment of clozapine-associated tardive dyskinesia.
Lin CC; Bai YM; Chen JY; Wang YC; Liou YJ
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):599-600. PubMed ID: 17920744
[No Abstract] [Full Text] [Related]
10. Augmentation of clozapine with amisulpride: a promising therapeutic approach to refractory schizophrenic symptoms.
Kämpf P; Agelink MW; Naber D
Pharmacopsychiatry; 2005 Jan; 38(1):39-40. PubMed ID: 15706467
[No Abstract] [Full Text] [Related]
11. Prevention of relapse in schizophrenia.
Curtin F
N Engl J Med; 2002 May; 346(18):1412-3; author reply 1412-3. PubMed ID: 11986420
[No Abstract] [Full Text] [Related]
12. Clozapine and amisulpride in refractory schizophrenia and alcohol dependence.
Dervaux A; Cazali J
J Clin Psychopharmacol; 2007 Oct; 27(5):514-6. PubMed ID: 17873688
[No Abstract] [Full Text] [Related]
13. Neuroleptic-induced reductions in serum dopamine-beta-hydroxylase in schizophrenia.
Goodnick PJ; Tong C; Duncavage MB; Meltzer HY
Biol Psychiatry; 1983 Dec; 18(12):1485-8. PubMed ID: 6140962
[No Abstract] [Full Text] [Related]
14. Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial.
Fleischhacker WW; Barnas C; Stuppäck CH; Unterweger B; Miller C; Hinterhuber H
Psychopharmacol Bull; 1989; 25(1):97-100. PubMed ID: 2570438
[No Abstract] [Full Text] [Related]
15. Clinical predictors of schizophrenic patient response to neuroleptics.
Korínková V
Act Nerv Super (Praha); 1989 Jun; 31(2):115-6. PubMed ID: 2572131
[No Abstract] [Full Text] [Related]
16. [Sulpiride: a neuroleptic agent of new generation with unique pharmacological qualities and rather wide range of clinical applications].
Pawłowski L
Psychiatr Pol; 1993; 27(2):199-205. PubMed ID: 8104350
[TBL] [Abstract][Full Text] [Related]
17. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
[TBL] [Abstract][Full Text] [Related]
18. Clinical practice guidelines. Treatment of schizophrenia.
Canadian Psychiatric Association
Can J Psychiatry; 2005 Nov; 50(13 Suppl 1):7S-57S. PubMed ID: 16529334
[No Abstract] [Full Text] [Related]
19. [Three antipsychotic drugs in the treatment of schizophrenia--a controlled and double-blind study].
Yang WJ
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1988 Oct; 21(5):277-80, 318-9. PubMed ID: 3069383
[No Abstract] [Full Text] [Related]
20. Amisulpride augmentation of clozapine in refractory schizophrenia.
Chiu HW; Ku YC; Li TC; Huang HT
J Neuropsychiatry Clin Neurosci; 2011; 23(3):E15. PubMed ID: 21948906
[No Abstract] [Full Text] [Related]
[Next] [New Search]
